Haemonetics reported mixed third-quarter results with a revenue decline but improved margins and strong cash flow generation. The company raised its full-year guidance, driven by performance in Plasma and Blood Management Technologies, while addressing challenges in Interventional Technologies.
Adjusted earnings per diluted share increased by 10.1% to $1.31 compared to the prior year.
positiveGross margin improved to 59.7% from 55.5% year-over-year, driven by a higher-margin product portfolio and innovation.
positiveOperating income increased by 14.2% to $67.4 million, with operating margin expanding to 19.9% from 16.9% year-over-year.
positiveCash flow from operating activities increased by 113.8% to $93.6 million, and free cash flow increased by 150.9% to $74.2 million year-over-year.
positiveFull-year fiscal 2026 guidance for total company reported revenue growth was raised to 1-3% from (1)-(4)%, and organic ex-CSL revenue growth was raised to 8-10% from 7-10%.
positiveFull-year fiscal 2026 adjusted earnings per diluted share guidance was raised to $4.90-$5.00 from $4.80-$5.00.
positiveFull-year fiscal 2026 free cash flow guidance was raised to $200M-$220M from $170M-$210M.
positiveTotal net revenue decreased by 2.7% to $339.0 million in the third quarter compared to the prior year.
negativeBlood Center revenue decreased by 19.6% year-over-year.
negativeInterventional Technologies revenue decreased by 11.4% year-over-year.
negativeOrganic revenue declined 1.2% in the third quarter, although organic ex-CSL revenue grew 7.5%.
attentionInventories, net decreased by $43.956 million from March 29, 2025 to December 27, 2025.
attentionMargin expansion indicates improving profitability and operational efficiency. Measured in basis points (bps): 100 bps = 1.0%.
| Segment | Current | Prior Yr | YoY | % Total |
|---|---|---|---|---|
Plasma | N/A | — | — | — |
Blood Center | N/A | — | — | — |
Hospital | N/A | — | — | — |
| Total Revenue | $0.00M | — | — | 100.0% |
Segment performance shows business unit health and growth drivers.
Forward-looking guidance is subject to change and does not constitute a guarantee. Actual results may differ materially from these estimates.
Special items are non-recurring events that may distort period-over-period comparisons. Analysts typically adjust for these when calculating normalized earnings.
Third quarter revenue growth, margin expansion, and cash flow reflect the underlying strength of our core businesses.
Plasma and Blood Management Technologies continue to drive our strong performance.
We are taking targeted actions to reestablish momentum in Interventional Technologies and prepare for a US launch of PerQseal Elite.
Commentary excerpts from earnings call transcripts provide management's perspective on performance, strategy, and outlook. Always review full transcripts for complete context.